Returning in September as a digital event, the 2nd  Gene Therapy for Ophthalmic Disorders meeting will target the industry’s translational challenges in targeting both rare and common ophthalmic disorders including wet AMD, dry AMD, DME, IRDs and more.

Dr Magali Taiel, Chief Medical Officer, will give an oral presentation on our lead product candidate LUMEVOQ® (GS010; lenadogene nolparvovec) as detailed below:


Thursday 23rd September 2021

Time:  3.30pm EST | 9.30pm CET

Lumevoq Gene Therapy in Leber Hereditary Optic Neuropathy (LHON):  Regulatory Considerations: US & Europe Regulators

  • LHON disease and its main clinical aspects
  • Walking through late-stage development of Lumevoq® gene therapy
  • Discussing regulatory pathways
  • Highlighting key learnings